Surrozen (NASDAQ:SRZN) Shares Gap Down - Here's What Happened

Surrozen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Surrozen shares opened sharply lower, falling from a prior close of $32.32 to $29.75, before last trading at $31.39.
  • Analyst views were mixed, but MarketBeat reported a “Moderate Buy” consensus from seven analysts and an average price target of $61.75.
  • Surrozen reported quarterly EPS of -$11.02, missing the consensus estimate of -$1.10 by $9.92; institutional investors own about 66.6% of its shares.
  • MarketBeat previews the top five stocks to own by December 1st.

Surrozen, Inc. (NASDAQ:SRZN - Get Free Report)'s stock price gapped down before the market opened on Wednesday. The stock had previously closed at $32.32, but opened at $29.75. Surrozen shares last traded at $31.3910, with a volume of 6,538 shares traded.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SRZN shares. Cantor Fitzgerald lifted their price target on shares of Surrozen from $40.00 to $62.00 and gave the company an "overweight" rating in a research report on Tuesday, November 10th. William Blair started coverage on shares of Surrozen in a research note on Thursday, August 20th. They issued an "outperform" rating and a $51.00 price objective on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Surrozen in a report on Thursday, October 15th. Wall Street Zen lowered Surrozen from a "hold" rating to a "sell" rating in a report on Saturday. Finally, Guggenheim set a $80.00 price target on shares of Surrozen and gave the stock a "buy" rating in a report on Wednesday, November 11th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $61.75.

Check Out Our Latest Stock Analysis on SRZN

Surrozen Stock Up 5.5%

The company has a market capitalization of $603.06 million, a PE ratio of -0.73 and a beta of 0.51. The company has a 50-day moving average price of $26.28 and a two-hundred day moving average price of $25.62.

Surrozen (NASDAQ:SRZN - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($11.02) earnings per share for the quarter, missing analysts' consensus estimates of ($1.10) by ($9.92). As a group, equities analysts anticipate that Surrozen, Inc. will post -6.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Algert Global LLC bought a new position in shares of Surrozen in the 3rd quarter worth $529,000. Integral Health Asset Management LLC purchased a new position in Surrozen in the third quarter worth $10,458,000. Jump Financial LLC bought a new position in Surrozen in the third quarter valued at $1,966,000. Global Retirement Partners LLC bought a new position in Surrozen in the third quarter valued at $45,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Surrozen by 37.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,000 shares of the company's stock valued at $160,000 after purchasing an additional 1,350 shares in the last quarter. Hedge funds and other institutional investors own 66.57% of the company's stock.

About Surrozen

(Get Free Report)

Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen's research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company's products are investigational and are not approved medicines.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Surrozen Right Now?

Before you consider Surrozen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surrozen wasn't on the list.

While Surrozen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines